Special Reports on Trastuzumab Deruxtecan 002 |

Discover the latest advancements in cancer treatment with our collection of articles and videos on trastuzumab deruxtecan, a promising targeted therapy changing the landscape for patients with HER2-positive cancers.

Trastuzumab deruxtecan shows promise in HER2-positive metastatic breast cancer

Treatment with trastuzumab deruxtecan (T-DXd) provides sustained antitumour activity and shows a consistent safety profile in patients... CLICK TO READ MORE

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population

Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of...CLICK TO READ MORE

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine. CLICK TO READ MORE

Ponatinib in CML and Ph+ ALL: Long-term efficacy and safety

Ponatinib is a highly potent agent recommended by international guidelines. Watch this video to gain insights from Dr Raymond Wong of the Division of Haematology, Department of Medicine & Therapeutics...CLICK TO WATCH THE VIDEO